Astro Pak launches decontamination services subsidiary

Published: 26-Jan-2010
Hi Tech Manufacturing Finance Cleaning

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

SixLog, headquartered in Santa Ana, California, performs decontamination services for equipment, rooms, entire buildings and modes of transport such as ambulances, trains and cruise ships.

The iHP bio decontamination technology was developed for military applications and this will be the first time that it will be used in commercial applications.

The company says technology can be used in open air and, once ionised, it acts like a gas as opposed to a vapour, providing excellent distribution properties and destroying micro-organisms even in hard-to-reach areas.

Steve Feinstein, formerly regional sales manager of a UK manufacturer of hydrogen peroxide vapour generators, has been appointed as SixLog's director of technology.

In addition to the company launch, SixLog has developed a website containing technical papers, presentations, and other downloads on biological decontamination and sterilisation.
  • Companies:
  • Instant Cleanroom Solutions
See more

You may also like

Finance

Pfizer completes $10bn acquisition of Metsera to kickstart its GLP-1 goals

Read more
The acquisition brings promising clinical-stage obesity candidates into Pfizer's portfolio, giving the pharma company a leg up in one of the most dynamic and high-growth therapeutic areas

Trending Articles

  1. Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion
  2. Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer
  3. Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
  4. Custom Pharmaceuticals launches new company to foster breakthrough drug development and strategic partnerships Custom Pharmaceuticals Ltd has launched Centrix Pharma Solutions, a new company dedicated to accelerating drug product development through collaboration with biotech firms and academic research
  5. Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth

You may also like

Finance

Pfizer completes $10bn acquisition of Metsera to kickstart its GLP-1 goals

The acquisition brings promising clinical-stage obesity candidates into Pfizer's portfolio, giving the pharma company a leg up in one of the most dynamic and high-growth therapeutic areas
Finance

CARBOGEN AMCIS secures refinancing to support growth and investment

CARBOGEN AMCIS today announced the successful refinancing and enhancement of its credit facilities through the banking syndication led by UBS Switzerland AG
Manufacturing

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
Finance

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
Finance

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer
Finance

Custom Pharmaceuticals launches new company to foster breakthrough drug development and strategic partnerships

Custom Pharmaceuticals Ltd has launched Centrix Pharma Solutions, a new company dedicated to accelerating drug product development through collaboration with biotech firms and academic research
Finance

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion
Subscribe now